Breast cancer is the most commonly diagnosed cancer in females, and the survival rate of breast cancer patients has been increased over the past decade for targeted therapies (1), including tamoxifen for patients with luminal A and luminal B subtypes of IBCa (40) and trastuzumab for HER2-positive IBCa patients (41, 42). This evidence concerns the gene ERBB2 and breast cancer.